ATE256698T1 - Biologisch aktive peptide und ihre zubereitungen und verwendungen - Google Patents

Biologisch aktive peptide und ihre zubereitungen und verwendungen

Info

Publication number
ATE256698T1
ATE256698T1 AT96910116T AT96910116T ATE256698T1 AT E256698 T1 ATE256698 T1 AT E256698T1 AT 96910116 T AT96910116 T AT 96910116T AT 96910116 T AT96910116 T AT 96910116T AT E256698 T1 ATE256698 T1 AT E256698T1
Authority
AT
Austria
Prior art keywords
preparations
biologically active
active peptides
derivatives
geodiamolide
Prior art date
Application number
AT96910116T
Other languages
English (en)
Inventor
Raymond Andersen
Chemistry
John Coleman
Silva Dilip De
Fangming Kong
Edward Piers
Debra Wallace
Michel Roberge
Biochemistry
Theresa Allen
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Application granted granted Critical
Publication of ATE256698T1 publication Critical patent/ATE256698T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT96910116T 1995-04-20 1996-04-22 Biologisch aktive peptide und ihre zubereitungen und verwendungen ATE256698T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9508195.6A GB9508195D0 (en) 1995-04-20 1995-04-20 Novel biologically active compounds and compositions,their use and derivation
PCT/GB1996/000942 WO1996033211A1 (en) 1995-04-20 1996-04-22 Biologically active peptides and compositions, their use

Publications (1)

Publication Number Publication Date
ATE256698T1 true ATE256698T1 (de) 2004-01-15

Family

ID=10773352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910116T ATE256698T1 (de) 1995-04-20 1996-04-22 Biologisch aktive peptide und ihre zubereitungen und verwendungen

Country Status (12)

Country Link
US (4) US6153590A (de)
EP (1) EP0839154B1 (de)
JP (2) JP4008493B2 (de)
AT (1) ATE256698T1 (de)
AU (1) AU5341696A (de)
CA (1) CA2220021C (de)
DE (1) DE69631141T2 (de)
DK (1) DK0839154T3 (de)
ES (1) ES2213173T3 (de)
GB (1) GB9508195D0 (de)
PT (1) PT839154E (de)
WO (1) WO1996033211A1 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2225325A1 (en) * 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
CA2360740A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
WO2002036135A2 (en) * 2000-11-06 2002-05-10 Pharma Mar, S.A. Compositions for antitumour treatment containing ecteinascidin 743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
WO2003082268A2 (en) * 2002-03-22 2003-10-09 Eisai Co. Ltd Hemiasterlin derivatives and uses thereof in the treatment of cancer
US7064211B2 (en) 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
US20040121965A1 (en) * 2002-09-20 2004-06-24 Wyeth Holdings Corporation Method of treating resistant tumors
EP1539682A2 (de) 2002-09-20 2005-06-15 Wyeth Holdings Corporation Verfahren zur herstellung von zwischenprodukten für die synthese von tubulinhemmern
SI1558354T1 (sl) * 2002-10-30 2010-05-31 Merck Sharp & Dohme Uporaba aminov amino kislin ali amino estrov kotmobilni fazni modikator v kromatografiji
US20070026478A1 (en) * 2002-11-21 2007-02-01 Wyeth Hemiasterlin affinity probes and their uses
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US7390910B2 (en) * 2003-08-08 2008-06-24 Wyeth Compounds for treating tumors
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) * 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
JP2007511509A (ja) * 2003-11-14 2007-05-10 ファルマ・マール・ソシエダード・アノニマ Et−743およびパクリタキセルの使用を含むガンの併用療法
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2008505862A (ja) * 2004-07-09 2008-02-28 ファルマ、マール、ソシエダード、アノニマ 予後分子マーカー
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
RS50822B (sr) * 2004-10-26 2010-08-31 Pharma Mar S.A., Sociedad Unipersonal Pegilovani lipozomalni doksorubicin u kombinaciji sa ekteinescidinom 743
KR101188691B1 (ko) * 2004-10-29 2012-10-09 파르마 마르 에스.에이. 엑티나시딘 및 디사카라이드를 포함하는 제제
JP2008522624A (ja) * 2004-12-09 2008-07-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘミアスタリン(hemiasterlin)アナログを使用する癌治療におけるチューブリンのアイソタイプのスクリーニング
AU2006244450A1 (en) * 2005-05-05 2006-11-16 Eisai Co., Ltd. Unsolvated and host-guest solvated crystalline forms of (2E,4S)-4-[(N-{[(2R)-1-isopropylpiperidin-2-yl]-carbonyl}-3-methyl-L-valyl)(methyl)amino)-2,5-dimethylhex-2-enoic acid and their pharmaceutical uses
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
US8106154B2 (en) * 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
WO2009050303A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for et-743 treatment
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
WO2011003005A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2012088124A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Tetrahydro-azacarboline mch-1 antagonists, methods of making, and uses thereof
CN103570603A (zh) * 2012-07-19 2014-02-12 杭州中肽生化有限公司 哈米特林的一种合成新方法
HK1220626A1 (zh) 2013-03-15 2017-05-12 The Centre For Drug Research And Development 具细胞毒性和抗有丝分裂的化合物以及其使用方法
KR102384740B1 (ko) 2013-12-27 2022-04-07 자임워크스 인코포레이티드 약물 접합체를 위한 설폰아마이드-함유 연결 시스템
MX2016008448A (es) 2013-12-27 2017-01-09 Zymeworks Inc Conjugados de var2csa-farmaco.
ES2905569T3 (es) 2014-09-17 2022-04-11 Zymeworks Inc Compuestos citotóxicos y antimitóticos y métodos para utilizarlos
WO2017066454A2 (en) 2015-10-14 2017-04-20 X-Therma, Inc. Compositions and methods for reducing ice crystal formation
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
CN111051329B (zh) * 2017-08-10 2024-07-30 住友制药株式会社 哈米特林衍生物及它们的抗体药物复合物
CA3072153A1 (en) * 2017-08-10 2019-02-14 Sumitomo Dainippon Pharma Co., Ltd. Antibody-drug conjugates including hemiasterlin derivative
CN113412271B (zh) * 2019-02-13 2024-10-22 住友制药株式会社 具有半胱氨酸残基的哈米特林衍生物
US20220202948A1 (en) * 2019-02-13 2022-06-30 Sumitomo Dainippon Pharma Co., Ltd. Agent for Eliminating Pluripotent Stem Cells
US12178879B2 (en) 2019-02-13 2024-12-31 Sumitomo Pharma Co., Ltd. Hemiasterlin derivative and antibody-drug conjugate thereof
JP7560255B2 (ja) * 2019-02-13 2024-10-02 住友ファーマ株式会社 ヘミアスタリン誘導体を含む抗体薬物複合体を含有する医薬

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2904512A1 (de) * 1979-02-07 1980-08-28 Troponwerke Gmbh & Co Kg Dehydropeptide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel
NZ194747A (en) * 1979-08-29 1988-11-29 Schering Ag 9h-pyrido(3,4-b)indol-3-ylcarboxylic acid derivatives
US4820691A (en) 1987-06-24 1989-04-11 E. R. Squibb & Sons, Inc. Amino acid 1,2-diketo derivatives as renin inhibitors
US5081225A (en) * 1989-02-09 1992-01-14 E. R. Squibb & Sons, Inc. Gram-positive and gram-negative antibacterial compounds from the microorganism, janthinobacterium lividum
US5340802A (en) * 1989-06-30 1994-08-23 Abbott Laboratories Peptide analog type-B CCK receptor ligands
WO1991004040A1 (en) * 1989-09-15 1991-04-04 Biomeasure, Inc. Treatment of colon cancer
FR2681075B1 (fr) * 1991-09-05 1994-09-16 Commissariat Energie Atomique Preparation enzymatique purifiee issue de chromobacterium violaceum, son procede d'obtention et son application a la production d'alpha,beta-dehydrotryptophanyl-peptides.
WO1993017701A1 (en) * 1992-03-12 1993-09-16 The Administrators Of The Tulane Educational Fund Endothelin receptor-binding peptides
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5661175A (en) * 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof

Also Published As

Publication number Publication date
US7772397B2 (en) 2010-08-10
CA2220021C (en) 2012-06-26
AU5341696A (en) 1996-11-07
JP2007031441A (ja) 2007-02-08
DK0839154T3 (da) 2004-04-19
US20050171137A1 (en) 2005-08-04
CA2220021A1 (en) 1996-10-24
DE69631141T2 (de) 2004-09-30
JP4008493B2 (ja) 2007-11-14
WO1996033211A1 (en) 1996-10-24
US7410951B2 (en) 2008-08-12
JPH11505211A (ja) 1999-05-18
JP4006466B2 (ja) 2007-11-14
US6870028B1 (en) 2005-03-22
DE69631141D1 (de) 2004-01-29
EP0839154A1 (de) 1998-05-06
PT839154E (pt) 2004-05-31
EP0839154B1 (de) 2003-12-17
GB9508195D0 (en) 1995-06-07
US6153590A (en) 2000-11-28
US20090088573A1 (en) 2009-04-02
ES2213173T3 (es) 2004-08-16

Similar Documents

Publication Publication Date Title
DE69631141D1 (de) Biologisch aktive peptide und ihre zubereitungen und verwendungen
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
ZA988826B (en) Acylsulfamoylbenzamides crop protection compositions comprising them and processes for their preparation
TR199800012T1 (xx) Piroloprimidinler ve preparasyon i�in tatbikler.
UY24244A1 (es) Derivados bicíclicos y policíclicos de isotiazolona
ES2133807T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas.
DE69729877D1 (de) Mycophenol bisphosponatverbindungen
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
TR199801195T2 (xx) Tedavide yararl� kinolin ve kinozilin bile�ikleri.
DE69724811D1 (de) Pentafluorobenzensulfonamide und analoge
ATE368054T1 (de) Verbindungen und methoden zur modulierung von occludin-abhängiger gewebepermeabilität
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
ES2181006T3 (es) Uso de amidas de acidos de piridil alcanos, piridil alquenos y/o piridil alquinos en el tratamiento de tumores o en inmunosupresion.
TR199903331T2 (xx) Farnesil protein transferas engelleyicileri.
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
TR199800623T2 (xx) Yeni amino asit t�revleri, m�stahzarlar� ve kullan�mlar�.
BR0014355A (pt) Derivados de sapogenina e seu uso no tratamento de disfunção cognitiva
HUP9800731A2 (hu) Eljárás ivarsejt osztódás stimulálására
AR021695A1 (es) 4,5-pirazinoxindoles, composicion farmaceutica y uso
EP0830456A4 (de) ISOLIERTES FrpB NUKLEINSÄUREMOLEKÜL UND ENTSPRECHENDE IMPFSTOFF
DE69825626D1 (de) Heterozyklische cytotoxische wirkstoffe
SE0003476D0 (sv) Compounds
BR0115121A (pt) Compostos n-((1,2,4)triazoloazinil)tiofenossulfonamida como herbicidas
ECSP044971A (es) Isoxazolopiridinonas y su uso en el tratamiento de enfermedad de parkinson
TR200000637T2 (tr) Benzoksazin ve benzotiazin türevleri ve bunların ilaçlarda kullanımı.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0839154

Country of ref document: EP

REN Ceased due to non-payment of the annual fee